News articles about Novogen Limited (NASDAQ:NVGN) have trended somewhat positive this week, Accern Sentiment reports. The research group identifies positive and negative news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Novogen Limited earned a news impact score of 0.13 on Accern’s scale. Accern also gave media stories about the biotechnology company an impact score of 44.1639541610912 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.
Novogen Limited (NASDAQ NVGN) opened at $2.95 on Wednesday. Novogen Limited has a 12-month low of $1.63 and a 12-month high of $7.60.
NVGN has been the subject of several recent research reports. Zacks Investment Research upgraded shares of Novogen Limited from a “sell” rating to a “hold” rating in a research report on Tuesday, September 5th. ValuEngine lowered shares of Novogen Limited from a “hold” rating to a “sell” rating in a research report on Tuesday, August 1st.
Novogen Limited Company Profile
Novogen Limited (Novogen) is an oncology biotechnology company, which is focused on developing cancer treatments. The Company is primarily engaged in pharmaceutical research and development. Novogen has two drug technology platforms (the Superbenzopyran (SBP) technology and Anti-tropomyosin (ATM)) yielding various drug candidates across a range of oncology indications.
Receive News & Ratings for Novogen Limited Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novogen Limited and related companies with MarketBeat.com's FREE daily email newsletter.